Gamma Pharmaceuticals Inc. announced that it has retained Burnham Securities Inc. and Nelson Mullins Riley & Scarborough LLP, to assist and advise Gamma management in a variety of corporate initiatives and to assist the Company in seeking financial and strategic alternatives. Peter Cunningham, Gamma's Chief Executive Officer, said, Gamma is at the most exciting point in the Company's history. After two years of challenges, where Management has had to bootstrap the Company forward to raise capital, formulate products, establish marketing and promotional platforms, and set up supply chain logistics, we have recently set in place several arrangements that position Gamma for potentially significant growth and profitability. Our previously announced ventures and agreements with Evander Holyfield, Jugular Inc., new distributors and an expanded retail customer base have transformed Gamma as a company. We are now rushing to confirm purchase orders and commission manufacturing to quickly ramp up to our contract minimums. As some commentators have said, 'the table for Gamma has been set.' The 'new' Gamma requires top-notch professional advisors to assist and advise Management in seeking financial and strategic alternatives designed to maximize shareholder value. Randal Stephenson, Managing Director of Burnham Securities Inc., said, We feel honored to assist and advise Gamma at this exciting time. The Company's recent initiatives have transformed Gamma almost overnight from a pre-revenue, developing business into a company with contractually guaranteed minimum sales volumes and annualized revenues of approximately $48 million. This fundamentally alters the Company's intrinsic value. Moreover, the new product lines under development with boxing legend Evander Holyfield and others are expected to generate additional sales volume and revenues significantly above these contract minimums. We are actively fielding numerous strategic inquiries and analyzing several financial and strategic alternatives, including a possible capital infusion by an equity sponsor, which is expected to create substantial additional shareholder value. Joe Cunningham, Gamma's Chief Financial Officer, said, We are very pleased to have a seasoned banker like Randal Stephenson and a venerable firm like Burnham as our investment bankers. Randal has been advising Gamma for the past two years through our development period, and he and Burnham were instrumental in guiding us through the several initiatives we recently announced. Now that the Company is positioned for substantial growth and profitability, Burnham's strong track record in debt and equity capital raising, mergers, and acquisitions advisory will prove invaluable. Burnham is actively developing and investigating several financial and strategic alternatives designed to further increase the value of Gamma. Nelson Mullins has proven to be exactly the legal advisor required by the 'new' Gamma. We just completed a flurry of joint ventures, long-term agreements and other corporate initiatives all of which are anticipated to be value-enhancing. Nelson Mullins' experience and commercial savvy helped us clarify, organize and conclude these sophisticated agreements and important initiatives. In addition, their calm hand supported our negotiations from start to finish. It is critical that we have a world class, sophisticated legal counsel like Nelson Mullins as Gamma continues to investigate opportunities, both here in the U.S. and overseas.

Gamma Pharmaceuticals Inc. announced the formation of a joint venture company with Jugular, Inc., replacing the brand licensing agreement in place between Gamma and Jugular since 2007. The new company, Gamma Jugular, LLC is closely integrated with Gamma's existing corporate infrastructure and distribution channels, and currently has three product lines and six SKUs with plans for expansion. Under the terms of the joint venture, Gamma will consolidate Gamma Jugular's performance into Gamma's financials.

Gamma Pharmaceuticals Inc. announced that it has entered into a multi-year agreement with one of North America's wholesale distribution organizations to distribute the full line of Gamma products. The Agreement, which is evergreen in duration, provides for minimum monthly volume purchases of Gamma products at agreed upon pricing per SKU. The contracted terms cover the sale of 40,000 cases per month of Gamma's branded products, which at full distribution equates to an annualized value of approximately $48.0 million.